The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $157.97

Today's change0.00 0.00%
Updated January 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $157.97

Today's change0.00 0.00%
Updated January 19 4:00 PM EST. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc closed at (U.S.)$157.97.

Over the last five days, shares are unchanged, but have gained 95.24% over the last 52 weeks. This security has outperformed the S&P 500 by 71.09% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $157.97
  • High--
  • Low--
  • Bid / Ask(U.S.) $155.01 / (U.S.) $159.35
  • YTD % change+5.41%
  • Volume0
  • Average volume (10-day)1,583,120
  • Average volume (1-month)1,494,839
  • Average volume (3-month)1,530,400
  • 52-week range(U.S.) $80.06 to (U.S.) $167.86
  • Beta1.57
  • Trailing P/E202.47×
  • P/E 1 year forward83.59×
  • Forward PEG1.22×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.78
Updated January 19 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+0.75%

Based on its net profit margin of 0.75%, Vertex Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue578544715459
Total other revenue--------
Total revenue578544715459
Gross profit506474668399
Total cost of revenue72714660
Total operating expense904491444419
Selling / general / administrative121127113110
Research & development455289274248
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)2564100
Other operating expenses, total1111
Operating income-3265327140
Interest income (expense), net non-operating-14-15-17-20
Gain (loss) on sale of assets--------
Other--------
Income before tax-4173625420
Income after tax-2913125028
Income tax, total-12644-7
Net income-1031824833
Total adjustments to net income000--
Net income before extra. items-1031824833
Minority interest188-13-25
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-1031824733
Inc. avail. to common incl. extra. items-1031824733
Diluted net income-1031824733
Dilution adjustment--------
Diluted weighted average shares250252251245
Diluted EPS excluding extraordinary itemsvalue per share-0.410.070.990.13
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.250.081.030.13